Lipids and hCRP concentrations in patients with dyslipidemia

Autor

  • Elżbieta Kimak Chair and Department of Laboratory Diagnostic, Medical University of Lublin, Poland Autor
  • Aleksandra Kimak Chair and Department of Conservative Dentistry with Endodonthic, Medical University of Lublin, Poland Autor
  • Barbara Tymczyna Chair and Department of Conservative Dentistry with Endodonthic, Medical University of Lublin, Poland Autor
  • Teresa Bachanek Chair and Department of Conservative Dentistry with Endodonthic, Medical University of Lublin, Poland Autor

DOI:

https://doi.org/10.12923/j.2084-980X/25.3/a.22

Słowa kluczowe:

lipids, hCRP, dyslipidemia

Abstrakt

Disturbances in lipids, and inflammations plays a key role in the pathogenesis of all stages of atherosclerosis. The aim of present study was to investigate concentration of hCRP, lipids (TC, TG, LDL-C, nonHDL-C, HDL-C) and lipid ratios (TC/HDL-C, LDL-C/HDL-C, TG/HDL-C) in patients with moderate dyslipidemia and compared to the healthy subjects, and relation between hCRP and lipids and lipid ratios. We studied 40 patients with moderately dyslipidemia (male and female) at the age between 21-63 years and the reference group. The reference group constituted of 14 subjects chosen from normolipidemic healthy individuals. The patients with moderate dyslipidemia had significantly increased hCRP, TG, LDL-C levels and significantly increased lipid ratios (TG/HDL, LDL-C/HDL-C). The concentration of hCRP was significantly positively correlated with TG, TC, LDL-C, nonHDL-C concentrations and TG/HDL-C, LDL-C/HDL-C ratios. We concluded that chronic inflammation disease can disturb lipids concentration and can accelerate atherosclerosis. However, these results are required further studies.

Bibliografia

1. Bajpai A.B., Goyal A., Sperling L.: Should we measure C-reactive protein on earth or just on JUPITER? Cin. Cardiol., 33, 190, 2010.

2. Bogavac-Stanojevic N., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V. et al.: Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach. Clin. Biochem., 40, 1000, 2007.

3. Clarfield M.B.: C-reactive protein: a new risk assessment tool for cardiovascular disease. JAOA, 105, 409, 2005.

4. Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, 2486, 2001.

5. Friedewald W.T., Levy R.I., Fredrickson D.S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem. 18, 499, 1972.

6. Hermans M.P., Sacks F.M., Ahn S.A., Rousseau M.F. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Disccriminant ratio and unbiased equivalence. Cardiovasc. Diabetol. 10, 20, 2011.

7. Kimak E., Hałabiś M. Serum hyperriglyceridemia as an important risk factor of chronic allograft failure in post-renal transplant patients. Annales UMCS, Sectio DDD, 22, 115, 2009.

8. Kimak E., Książek A., Baranowicz-Gąszczyk I., Solski J.: Disturbed lipids, lipoproteins and triglyceride rich-lipoproteins as well as fasting and nonfasting non-high–density lipoprotein cholesterol in post-renal transplant patients. Ren. Fail., 29, 705, 2007.

9. Pischon T., Girman G. J., Sacks F.M. et al.: Non-high-density lipoprotein cholesterol and Apolipoprotein B in the predictor of coronary heart disease in mem. Circulation, 112, 3366, 2005.

10. Rana J.S., Boekholdt M.: Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol? Curr. Opin. Cardiol., 25, 622, 2010.

11. Ridker P.M., Rifai N., Bradwin G. et al.: Non-HDL cholesterol, apolipoproteins AI and apoB100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA, 294, 326, 2005.

12. Taniguchi H., Momiyama Y., Ohmori R. et al.: Association of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with sable coronary artery disease. Atherosclerosis, 178, 173, 2005.

13. Wang L., Gill R., Pedersen T. et al.: Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid. Res., 50, 204, 2009.

Pobrania

Opublikowane

2012-07-01

Numer

Tom 25 Nr 3 (2012): Current Issues of Pharmacy and Medical Sciences

Dział

Artykuły

Licencja

Prawa autorskie (c) 2012 Autorzy

Creative Commons License

Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Jak cytować

Kimak, E., Kimak, A., Tymczyna, B., & Bachanek, T. (2012). Lipids and hCRP concentrations in patients with dyslipidemia. Current Issues in Pharmacy and Medical Sciences, 25(3), 322-324. https://doi.org/10.12923/j.2084-980X/25.3/a.22